124 related articles for article (PubMed ID: 18814837)
1. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
Van Aller GS; Carson JD; Fernandes C; Lehr R; Sinnamon RH; Kirkpatrick RB; Tummino PJ; Luo L
Anal Biochem; 2008 Dec; 383(2):311-5. PubMed ID: 18814837
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.
Beeton CA; Chance EM; Foukas LC; Shepherd PR
Biochem J; 2000 Sep; 350 Pt 2(Pt 2):353-9. PubMed ID: 10947948
[TBL] [Abstract][Full Text] [Related]
4. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
[TBL] [Abstract][Full Text] [Related]
5. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma.
Fuchikami K; Togame H; Sagara A; Satoh T; Gantner F; Bacon KB; Reinemer P
J Biomol Screen; 2002 Oct; 7(5):441-50. PubMed ID: 14599360
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of the regulatory subunits for phosphatidylinositol 3-kinase in response to motor nerve injury.
Okamoto T; Namikawa K; Asano T; Takaoka K; Kiyama H
Brain Res Mol Brain Res; 2004 Nov; 131(1-2):119-25. PubMed ID: 15530660
[TBL] [Abstract][Full Text] [Related]
8. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
[TBL] [Abstract][Full Text] [Related]
9. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
Garcia-Echeverria C; Sellers WR
Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
[TBL] [Abstract][Full Text] [Related]
10. Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay.
Boldyreff B; Rasmussen TL; Jensen HH; Cloutier A; Beaudet L; Roby P; Issinger OG
J Biomol Screen; 2008 Dec; 13(10):1035-40. PubMed ID: 19036708
[TBL] [Abstract][Full Text] [Related]
11. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
12. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
Vogt PK; Bader AG; Kang S
Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
[TBL] [Abstract][Full Text] [Related]
13. Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation.
Kim JE; Shepherd PR; Chaussade C
Biochem Biophys Res Commun; 2009 Feb; 379(4):830-4. PubMed ID: 19114029
[TBL] [Abstract][Full Text] [Related]
14. Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells.
Park EY; Wilder ET; Chipuk JE; Lane MA
Mol Carcinog; 2008 Apr; 47(4):264-74. PubMed ID: 17918208
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
16. A new evaluation method for quantifying PI3K activity by HTRF assay.
Sugita H; Dan S; Kong D; Tomida A; Yamori T
Biochem Biophys Res Commun; 2008 Dec; 377(3):941-5. PubMed ID: 18952065
[TBL] [Abstract][Full Text] [Related]
17. Regulation of phosphoinositide 3-kinase expression in health and disease.
Kok K; Geering B; Vanhaesebroeck B
Trends Biochem Sci; 2009 Mar; 34(3):115-27. PubMed ID: 19299143
[TBL] [Abstract][Full Text] [Related]
18. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
[TBL] [Abstract][Full Text] [Related]
19. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?
Geering B; Cutillas PR; Vanhaesebroeck B
Biochem Soc Trans; 2007 Apr; 35(Pt 2):199-203. PubMed ID: 17371237
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
